RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimer's Disease

A. Hadar*, I. Gozes, D. Gurwitz

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

3 Scopus citations


The discovery of early biomarkers for Alzheimer's disease (AD) is required for early diagnosis and personalized preventive therapy. In an innovative approach, we have used genome-wide transcriptomic profiling of lymphoblastoid cell lines (LCLs) from healthy individuals and identified genes that predict sensitivity to A?. RGS2 (regulator of G-protein signaling 2) had lower expression in healthy individuals' LCLs exhibiting higher A? sensitivity. Interestingly, RGS2 showed lower expression in AD LCLs compared to healthy controls. Moreover, SIRT1 (Sirtuin 1) was downregulated in AD LCLs. Thus, LCLs transcriptomics identified RGS2, a key regulator of G protein coupled receptors and neuronal plasticity, as a novel AD biomarker. RGS2 and SIRT1 expression levels were positively correlated and both have been implicated as neuroprotective and involved in the renin-angiotensin-aldosterone system. Individual LCLs may thus serve, as surrogate for brain cells, and may point to altered transcriptomic profiles that could be implicated in AD pathology.

Original languageEnglish
Title of host publicationNeuroprotection in Alzheimer's Disease
PublisherElsevier Inc.
Number of pages13
ISBN (Electronic)9780128037126
ISBN (Print)9780128036907
StatePublished - 20 Jan 2017


  • Alzheimer's disease
  • Amyloid ?
  • DLGAP1
  • Genomic biomarkers
  • Mild cognitive impairment (MCI)
  • RGS2
  • Renin-angiotensin-aldosterone system
  • SIRT1


Dive into the research topics of 'RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this